Inhibrx Announces Participation in Upcoming Investor Conference

On February 1, 2021 Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, reported that the Company will be presenting at the following upcoming virtual investor conference (Press release, Inhibrx, FEB 1, 2021, View Source [SID1234574473]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time
The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx’s website at View Source The webcast will be available for 60 days following the event.